ALKERMES | ALKS - Interest Expense On Debt



ALKERMES reported $0 in Interest Expense on Debt for its fiscal quarter ending in June of 2025.


Interest Expense On Debt Change Date
AbbVie USD 700M 90M Mar/2025
Acadia Pharmaceuticals 0 4.12M Sep/2024
ALKERMES USD 0 0 Jun/2025
Amgen USD 694M 29M Jun/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.68M 184K Jun/2025
Bristol-Myers Squibb USD 485M 9M Jun/2025
Eli Lilly USD 249M 5.3M Jun/2025
Gilead Sciences USD 254M 6M Jun/2025
Ionis Pharmaceuticals USD 19M 0 Jun/2025
J&J USD 128M 9M Mar/2025
Merck USD 305M 8M Jun/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Otsuka Holdings 9.73B 4.01B Jun/2025
Pfizer USD 654M 0 Jun/2025
Regeneron Pharmaceuticals USD 3.6M 5.1M Jun/2025
Vertex Pharmaceuticals USD 3.7M 900K Jun/2025